TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18398639

Group type: EXPERIMENTAL
Intervention: FemoStop (mechanical compression)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: AngioSeal (anchor and collagen sponge)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Perclose (nonabsorbable suture)
Number of subjects: 77
Study: 15973831

Group type: EXPERIMENTAL
Intervention: Prototype power toothbrush (Blend‐a‐Med Power)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control manual toothbrush (Lion Dentor Systema)
Number of subjects: 86
Study: 12818953

Group type: EXPERIMENTAL
Intervention: 1.0 mg intranasal hydromorphone hydrochloride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2.0 mg intranasal hydromorphone hydrochloride
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2.0 mg intravenous hydromorphone hydrochloride
Number of subjects: 24
Study: 10784386

Group type: EXPERIMENTAL
Intervention: Extracorporeal photochemotherapy (ECP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7960542

Group type: EXPERIMENTAL
Intervention: Nd-Yag laser treatment
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Nd-Yag laser treatment combined with transurethral resection (TUR)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Transurethral resection (TUR)
Number of subjects: 116
Study: 3110444

Group type: EXPERIMENTAL
Intervention: ProcalAmine (3% amino acids, 3% glycerol, and electrolytes)
Number of subjects: 25

Group type: COMPARATOR
Intervention: FreAmineIII + dextrose and electrolytes
Number of subjects: 25
Study: 31885129

Group type: EXPERIMENTAL
Intervention: Mentored Planning to Be Active (MBA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Planning to Be Active (PBA)
Number of subjects: 0
Study: 29705707

Group type: EXPERIMENTAL
Intervention: Alcohol at 60 mg/dL
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 26884472

Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (2 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (3 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intramuscular glucagon (weight-based dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intramuscular glucagon (1 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (2 mg and 3 mg)
Number of subjects: 48
Study: 27403406

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg/mL), administered via intratympanic injection, 0.5 ml, once every 2 days for 3 times
Number of subjects: 50

Group type: COMPARATOR
Intervention: Methylprednisolone (40 mg/mg), administered via intratympanic injection, 0.5 ml, along with bicarbonate
Number of subjects: 50
Study: 22833175

Group type: EXPERIMENTAL
Intervention: Selective head-cooling treatment (therapeutic hypothermia)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (rectal temperature 37°C)
Number of subjects: 14
Study: 21830388

Group type: EXPERIMENTAL
Intervention: Eating lunch before colonoscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fasting before colonoscopy
Number of subjects: 0
Study: 19863361

Group type: EXPERIMENTAL
Intervention: FSC 250/50
Number of subjects: 797

Group type: COMPARATOR
Intervention: SAL
Number of subjects: 797
Study: 16759927

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone patches (300 microg T daily)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 15025600

Group type: EXPERIMENTAL
Intervention: 5 mg kg(‐1) of aminophylline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study: 11708704

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (20 g per day for 6 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10380782

Group type: EXPERIMENTAL
Intervention: Perfume exposure during airway exposure (with eyes covered)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Perfume exposure during eye exposure (with fresh air inhaled)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo exposure (control)
Number of subjects: 11
Study: 7711763

Group type: EXPERIMENTAL
Intervention: 5 cm positive heel inclination
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0 heel inclination
Number of subjects: 15
Study: 10313784

Group type: EXPERIMENTAL
Intervention: Back School program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 826516

Group type: EXPERIMENTAL
Intervention: One Prompt plus $5 Incentive
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Three Prompt (Note, Telephone Contact, Home Visit)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Note Only
Number of subjects: 51

Group type: COMPARATOR
Intervention: Three-Prompt
Number of subjects: 51
Study: 31281111

Group type: EXPERIMENTAL
Intervention: 10-Meter Walking Test (10MWT) - first trial
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10-Meter Walking Test (10MWT) - second trial
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Interrater reliability measures
Number of subjects: 50
Study: 28333318

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone 30 mg daily (10 mg three times daily)
Number of subjects: 1031

Group type: COMPARATOR
Intervention: Micronized vaginal progesterone (MVP) 600 mg daily (200 mg three times daily)
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone
Number of subjects: 1031

Group type: COMPARATOR
Intervention: Micronized vaginal progesterone (MVP)
Number of subjects: 1031
Study: 25973439

Group type: EXPERIMENTAL
Intervention: apremilast 20 mg BID
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: apremilast 30 mg BID
Number of subjects: 504

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 504
Study: 23039088

Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22078686

Group type: EXPERIMENTAL
Intervention: Woodstove with chimney (n=269)
Number of subjects: 534

Group type: COMPARATOR
Intervention: Open woodfires (n=265)
Number of subjects: 534
Study: 19907956

Group type: EXPERIMENTAL
Intervention: Percutaneous Needle Aspiration (PNA)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Percutaneous Catheter Drainage (PCD)
Number of subjects: 72
Study: 16289977

Group type: EXPERIMENTAL
Intervention: DAG oil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Triacylglycerol oil
Number of subjects: 24
Study: 12852715

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 0
Study: 10691232

Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nitroprusside administration
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (passive insulation)
Number of subjects: 50
Study: 9313323

Group type: EXPERIMENTAL
Intervention: Nocturnal penile tumescence monitoring by RigiScan device
Number of subjects: 64

Group type: COMPARATOR
Intervention: Multidisciplinary diagnostic approach (including dynamic color Doppler sonography and pharmaco-cavernosometry)
Number of subjects: 64
Study: 8490070

Group type: EXPERIMENTAL
Intervention: High-potency marijuana cigarettes
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low-potency marijuana cigarettes
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo cigarette
Number of subjects: 35
Study: 3492950

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole, 320 mg/d-1600 mg/d for 2 or 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ampicillin, 2 g/d for 2 or 6 weeks
Number of subjects: 60
Study: 29476079

Group type: EXPERIMENTAL
Intervention: Co-localization methods to identify eQTL-meQTL pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-localization methods
Number of subjects: 0
Study: 27455155

Group type: EXPERIMENTAL
Intervention: Teres ligament coverage
Number of subjects: 152
Study: 24973959

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (40 mg/m2 once weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0
Study: 22179956

Group type: EXPERIMENTAL
Intervention: Intensive group (mean 1.06 hypoglycemic episodes in 7 days)
Number of subjects: 10096

Group type: COMPARATOR
Intervention: Standard group (mean 0.29 hypoglycemic episodes in 7 days)
Number of subjects: 10096

Group type: EXPERIMENTAL
Intervention: Intensive group (5.8% unrecognized hypoglycemia at visits)
Number of subjects: 10096

Group type: COMPARATOR
Intervention: Standard group (2.6% unrecognized hypoglycemia at visits)
Number of subjects: 10096
Study: 20125186

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (CC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Decaffeinated coffee (DC)
Number of subjects: 20
Study: 18305548

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 36
Study: 15943857

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 57
Study: 12615792

Group type: EXPERIMENTAL
Intervention: Azimilide (100 to 125 mg once daily for 6 or 9 months)
Number of subjects: 1380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: Azimilide
Number of subjects: 1380
Study: 10228046

Group type: EXPERIMENTAL
Intervention: rhumAb-E25 infusions biweekly for 46 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinuation of rhumAb-E25 infusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basophils cultured with IgE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basophils cultured without IgE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basophils cultured with IgG
Number of subjects: 0
Study: 8924256

Group type: EXPERIMENTAL
Intervention: Brief group counseling (3-hour skills training)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 329
Study: 2029988

Group type: EXPERIMENTAL
Intervention: recombinant interferon-alpha-2b
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: prednisone (after a 6 wk course)
Number of subjects: 21

Group type: COMPARATOR
Intervention: HLA class I antigen on hepatocytes
Number of subjects: 21
Study: 7122702

Group type: EXPERIMENTAL
Intervention: Removable rigid dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional elastic bandages
Number of subjects: 0
Study: 31202210

Group type: EXPERIMENTAL
Intervention: Manual therapy combined with cryotherapy (MT-C)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Kinesiotherapy combined with cryotherapy (KIN-C)
Number of subjects: 128
Study: 28644246

Group type: EXPERIMENTAL
Intervention: In-hospital exercise intervention during neoadjuvant chemotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 20
Study: 26444846

Group type: EXPERIMENTAL
Intervention: Infórmate website exposure
Number of subjects: 282

Group type: COMPARATOR
Intervention: Usual care controls
Number of subjects: 282
Study: 24474552

Group type: EXPERIMENTAL
Intervention: Red Bull (355 mL)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Tap water (355 mL)
Number of subjects: 25
Study: 21961239

Group type: EXPERIMENTAL
Intervention: Local injection of 2 ml of 80,000 U gentamycin + 2 ml of lidocaine, twice a week for 3 weeks
Number of subjects: 163

Group type: COMPARATOR
Intervention: Normal saline + 2 ml of lidocaine, twice a week for 3 weeks (Control Group B)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Normal saline + 2 ml of lidocaine, twice a week for 3 weeks (Control Group C)
Number of subjects: 163
Study: 19105706

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Raloxifene (60 mg/day)
Number of subjects: 0
Study: 17344487

Group type: EXPERIMENTAL
Intervention: Medium Calcium meal (MC meal: 84 mg/MJ)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High Calcium meal (HC meal: 172 mg/MJ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Calcium carbonate supplement (Suppl meal: 183 mg/MJ)
Number of subjects: 18
Study: 15550602

Group type: EXPERIMENTAL
Intervention: Trunk flexion over 45 degrees for 1 hour and 45 minutes per week (90th centile)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Low decision authority and high work demands (psychosocial factors)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Physical factors
Number of subjects: 523
Study: 11560848

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided stent implantation
Number of subjects: 550

Group type: COMPARATOR
Intervention: Angiography-guided stent implantation
Number of subjects: 550
Study: 9476460

Group type: EXPERIMENTAL
Intervention: Nestroft test in Group I (beta-thalassemia major families)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Nestroft test in Group II (normal children)
Number of subjects: 253
Study: 7700069

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibition
Number of subjects: 0
Study: 2444241

Group type: EXPERIMENTAL
Intervention: Extradural administration of meptazinol 90 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) administration of meptazinol 90 mg
Number of subjects: 32
Study: 31388637

Group type: EXPERIMENTAL
Intervention: Lidocaine with adrenaline
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 69
Study: 29706497

Group type: EXPERIMENTAL
Intervention: Supervised physical training after RYGB
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RYGB (surgery)
Number of subjects: 60
Study: 26391263

Group type: EXPERIMENTAL
Intervention: Combined TXA (1 g IV + 2 g local)
Number of subjects: 210

Group type: COMPARATOR
Intervention: IV TXA (1.5 g)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Local TXA (3 g)
Number of subjects: 210
Study: 24206971

Group type: EXPERIMENTAL
Intervention: Clopidogrel post CABG
Number of subjects: 953

Group type: COMPARATOR
Intervention: No clopidogrel post CABG
Number of subjects: 953
Study: 22935812

Group type: EXPERIMENTAL
Intervention: Particle repositioning maneuver (PRM)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Brandt-Daroff exercise (B-D exercise)
Number of subjects: 81
Study: 19615825

Group type: EXPERIMENTAL
Intervention: Chewing gum (sugar-free, various flavors and brands)
Number of subjects: 177
Study: 18793929

Group type: EXPERIMENTAL
Intervention: Ultrasonics and rotary nickel‐titanium instruments (group B)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Rotary instruments alone (group A)
Number of subjects: 93
Study: 15915009

Group type: EXPERIMENTAL
Intervention: Formoterol via HFA pMDI
Number of subjects: 500

Group type: COMPARATOR
Intervention: Formoterol via DPI
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Formoterol via HFA pMDI and DPI
Number of subjects: 500
Study: 12604935

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-measured home blood pressure measurements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambulatory white-coat hypertension (WCH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-measured white-coat hypertension (WCH)
Number of subjects: 0
Study: 10817726

Group type: EXPERIMENTAL
Intervention: AMD-3100 intravenous infusion at 10, 20, 40, or 80 microg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AMD-3100 subcutaneous injection at 40 or 80 microg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AMD-3100 oral dosing at 80 and 160 microg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AMD-3100 intravenous dose at 80 microg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic parameters
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AMD-3100 intravenous dose
Number of subjects: 12
Study: 8877991

Group type: EXPERIMENTAL
Intervention: Octreotide 0.10 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Octreotide 0.05 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Octreotide 0.10 mg and 0.05 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Responder patients
Number of subjects: 20
Study: 1839442

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg once daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diltiazem (30 mg three times daily)
Number of subjects: 100
Study: 6601279

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the right quadriceps femoris muscle (n = 20)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Isometric strengthening of the quadriceps femoris muscle (n = 19)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 58
Study: 28233481

Group type: EXPERIMENTAL
Intervention: Postoperative infection group (N=52)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Non-infected group (N=74)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both groups (infected and non-infected)
Number of subjects: 126
Study: 29291429

Group type: EXPERIMENTAL
Intervention: Phytosterols (PS, 2 g/d)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Curcumin (CC, 200 mg/d)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combination of PS and Curcumin (PS-CC, 2 g/d-200 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (PL, no phytosterols or curcumin)
Number of subjects: 70
Study: 25059838

Group type: COMPARATOR
Intervention: Iron supplementation
Number of subjects: 737

Group type: COMPARATOR
Intervention: Micronutrient supplement
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Non-iron groups
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Iron and multiple micronutrient supplementation
Number of subjects: 737
Study: 23474741

Group type: EXPERIMENTAL
Intervention: SRP + aPDT
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 30
Study: 22943820

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 55
Study: 19882739

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy for weight gain prevention (IPT-WG)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard-of-care health education group
Number of subjects: 38
Study: 17336785

Group type: EXPERIMENTAL
Intervention: Imagining eating a slice of chocolate cake while performing a simple reaction time task
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Imagining drinking a glass of water while performing a simple reaction time task
Number of subjects: 58

Group type: COMPARATOR
Intervention: Post-task consumption information (consumption vs no consumption)
Number of subjects: 58
Study: 15801937

Group type: EXPERIMENTAL
Intervention: Ginkgo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ginger
Number of subjects: 12

Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 12
Study: 12635796

Group type: EXPERIMENTAL
Intervention: Low-load muscular training with moderate restriction of blood flow (group R, n = 22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low-load muscular training with moderate restriction of blood flow (group R, n = 8)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Training without restriction (group N, n = 22)
Number of subjects: 44
Study: 10227417

Group type: EXPERIMENTAL
Intervention: Innovations in informed consent methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 8703997

Group type: EXPERIMENTAL
Intervention: Smoke-free policy program
Number of subjects: 155

Group type: COMPARATOR
Intervention: Non smoke-free policy program
Number of subjects: 155
Study: 2071257

Group type: EXPERIMENTAL
Intervention: L-alpha-glycerylphosphorylcholine (L-alpha-GFC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: COMPARATOR
Intervention: Scopolamine
Number of subjects: 32
Study: 6395907

Group type: EXPERIMENTAL
Intervention: EMG biofeedback (visual and auditory EMG training)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Relaxation treatment (modified PMR and imagery exercises)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (stretching exercises)
Number of subjects: 30
Study: 29661902

Group type: EXPERIMENTAL
Intervention: 0.45 mg/d oral conjugated equine estrogen (oCEE)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 50 μg/d transdermal 17β‐estradiol (tE2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 26171861

Group type: EXPERIMENTAL
Intervention: 10 grams of oral creatine/day
Number of subjects: 1741
Study: 23635615

Group type: EXPERIMENTAL
Intervention: Specific ambulation goals
Number of subjects: 146

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 146
Study: 20666269

Group type: EXPERIMENTAL
Intervention: Combination therapy with amlodipine and fosinopril given in the morning and at bedtime (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Concomitant administration of amlodipine and fosinopril in the morning (group B)
Number of subjects: 40
Study: 18789680

Group type: EXPERIMENTAL
Intervention: Berberine plus radiation therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo plus radiation therapy
Number of subjects: 90
Study: 18076248

Group type: EXPERIMENTAL
Intervention: Velocity-spectrum training of the hip (8 training sessions over 4 weeks, unilateral hip flexion/extension and hip abduction/adduction, starting at 60 degrees x sec(‐1) and increasing to 180, 300, and 400 degrees x s(‐1))
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (maintained regular activity throughout the 4-week span)
Number of subjects: 23
Study: 12663231

Group type: EXPERIMENTAL
Intervention: Probucol 500 mg daily for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11115310

Group type: EXPERIMENTAL
Intervention: Telephone reminder group
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Mail reminder group
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Sequential mail/telephone reminder group
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 264